Let’s go back 50 years. We have a 7-year-old child who is bored in school and disrupts classes. Back then, he was called lazy. Today, he is said to suffer from ADHD (Attention Deficit Hyperactivity Disorder). . . . Every child who’s not doing well in school is sent to see a pediatrician, and the pediatrician says: “It’s ADHD; here’s Ritalin.

In reality, almost 90 percent of these 5.4 million kids don’t actually have any kind of abnormal dopamine metabolism. The real problem is that if a drug, considered the easy route, is available to doctors, they’ll make the corresponding diagnosis.

Dr Eisenberg made a excellent and often luxurious living off of his “fictitious disease,” thanks to pharmaceutical sales.

According to Psychiatric News.

He received the Ruane Prize for Child and Adolescent Psychiatry Research and was a leader in child psychiatry for more than 40 years through his work in pharmacological trials, research, teaching, and social policy and for his theories of autism and social medicine.

The medical industry is using the guise of helping children to depersonalize and disconnect our children from a healthy, and somewhat normal upbringing. Parents are pumping these drugs into their kids with blissfull abanon, subjecting them to nothing of what the world has to offer, when in fact all these children are looking for stimulation and a fullfilled upbringing.

In the United States, 1 out of 10 boys among 10-year-olds takes medication for ADHD on a daily basis . . . with increasing tendency.

American psychologist Lisa Cosgrove and others reveal the facts in their study “Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry.” They found that “of the 170 DSM panel members 95 (56 percent) had one or more financial associations with companies in the pharmaceutical industry. One hundred percent of the members of the panels on ‘Mood Disorders’ and ‘Schizophrenia and Other Psychotic Disorders’ had financial ties to drug companies.”

And they are reaping major benefits from this “fictitious disease.” For example, the assistant director of the Pediatric Psychopharmacology Unit at Massachusetts General Hospital and associate professor of Psychiatry at Harvard Medical School received “$1 million in earnings from drug companies between 2000 and 2007.”

Marc-André Gagnon and Joel Lexchin, a long-time researcher of pharmaceutical promotion, performed a study which shows that the U.S. pharmaceutical industry spent 24.4 percent of the sales dollar on promotion, versus 13.4 percent for research and development in 2004. That is almost twice as much money to push their drugs on people than the amount to research to make sure it they’re safe!